Search Results
Your search for ,are matches 22257 pages
Showing 13151 - 13200Julian Schink, MD, Named Chief of Gynecologic Oncology at Cancer Treatment Centers of America
Cancer Treatment Centers of America (CTCA) has named Julian Schink, MD, as Chief of Gynecologic Oncology. He will also serve as Medical Director of Gynecologic Oncology and Medical Oncology at CTCA at the Midwestern Regional Medical Center in Zion, Illinois. A nationally renowned, Board-certified...
Launch of Watson-Powered Genomic Sequencing Service to Help Physicians Bring Precision Cancer Treatments to Patients Nationwide
On July 27, IBM Watson Health and Quest Diagnostics announced the launch of IBM Watson Genomics from Quest Diagnostics, a new service that helps advance precision medicine by combining cognitive computing with genomic tumor sequencing. Memorial Sloan Kettering Cancer Center (MSK) will...
Two San Diego Nonprofits to Receive 2017 ASTRO Survivor Circle Grants
The American Society for Radiation Oncology (ASTRO) will award its annual Survivor Circle grants to two San Diego–based cancer support charities: Cancer Angels of San Diego and The Seany Foundation. Each organization will receive an $8,500 grant to support its programs for those who have been...
NETRF Commits $4 Million for Neuroendocrine Tumor Research
The Neuroendocrine Tumor Research Foundation (NETRF) has announced its largest research commitment ever—$4 million in collaborative grants—most from its new Accelerator Grants program to study neuroendocrine tumors, a widely misunderstood, commonly misdiagnosed cancer type without adequately...
Effect of BRAF V600E Mutation on Outcome in Pediatric Low-Grade Gliomas
An analysis reported by Lassaletta et al in the Journal of Clinical Oncology showed that BRAF V600E mutation is associated with a poor outcome in pediatric low-grade gliomas treated with standard adjuvant therapy. Study Details The study involved patients with low-grade gliomas with long-term...
Comparison of Circulating Tumor DNA and Metastatic Tissue Biopsy in Identifying Mutations in Prostate Cancer
In a study reported in the Journal of the National Cancer Institute, Wyatt et al found high agreement between driver mutations in plasma circulating tumor DNA (ctDNA) and metastatic tissue biopsy in castration-resistant prostate cancer. Mutations Identified in ctDNA In the study, targeted...
10-Year Follow-up on Adjuvant Tamoxifen and Exemestane in Postmenopausal Early Breast Cancer
The 10-year follow-up of the phase III TEAM trial has shown that exemestane alone and sequential tamoxifen/exemestane provide similar outcomes as adjuvant endocrine therapy in postmenopausal women with hormone receptor–positive early breast cancer. The findings were reported in The Lancet...
FDA Approves Enasidenib in Relapsed or Refractory Acute Myeloid Leukemia
Today, the U.S. Food and Drug Administration (FDA) approved enasidenib (Idhifa) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic, the RealTime IDH2 Assay, which ...
FDA Grants Acalabrutinib Breakthrough Therapy Designation for the Treatment of Mantle Cell Lymphoma
Today, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for acalabrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Acalabrutinib is a highly selective, potent Bruton tyrosine kinase (BTK)...
FDA Approves Nivolumab in MSI-H or dMMR Metastatic Colorectal Cancer
Today, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) injection for intravenous use for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer...
Tremelimumab in Previously Treated Advanced Malignant Mesothelioma
In the randomized phase IIB DETERMINE trial, the cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) inhibitor tremelimumab did not improve overall survival vs placebo as second- or third-line treatment of relapsed malignant mesothelioma. These findings were reported in The Lancet Oncology...
New ASCO Recommendations for Controlling Nausea and Vomiting Related to Cancer Treatment
An update of the ASCO Clinical Practice Guideline covers new medicines for nausea and vomiting related to cancer treatment. The update, issued by Hesketh et al in the Journal of Clinical Oncology today, provides new evidence-based information on the appropriate use of olanzapine, neurokinin 1...
FDA Grants Venetoclax Breakthrough Therapy Designation for Geriatric Patients With Acute Myeloid Leukemia
On July 28, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for venetoclax (Venclexta) in combination with low-dose cytarabine for elderly patients with previously untreated acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. FDA...
Fulvestrant Receives EC Approval as First-Line Therapy for Advanced Breast Cancer
On July 26, the European Commission (EC) approved fulvestrant (Falsodex) for the treatment of estrogen receptor–positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy. The EC approval is based on pivotal data from the...
FDA Grants Durvalumab Breakthrough Therapy Designation for Patients With Locally Advanced Unresectable NSCLC
On July 31, AstraZeneca and MedImmune (AstraZeneca’s global biologics research and development arm) announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for durvalumab (Imfinzi) for the treatment of patients with locally advanced,...
Initial Progression-Free Survival Results From the MYSTIC Trial in Stage IV NSCLC
On July 27, researchers announced the progression-free survival (PFS) results for the phase III MYSTIC trial, a randomized, open-label, multicenter, global trial of durvalumab (Imfinzi) monotherapy or durvalumab in combination with tremelimumab vs platinum-based standard-of-care chemotherapy in...
Breast Cancer Survivor Preferences for Providers of Aspects of Primary Care After Cancer Treatment
In a study reported in the Journal of Clinical Oncology, Wallner et al found that minority women vs white women and women with a lower vs higher attained education level were more likely to prefer oncology-directed care vs primary care provider–directed care for aspects of care normally...
Study Finds HER2 Mutations in 3% of Lung Cancers
The Lung Cancer Mutation Consortium at the University of Colorado Cancer Center reported that 24 of 920 patients (3%) with advanced-stage lung cancer in a recent study had mutations in the gene HER2. According to the study, published by Pillai et al in Cancer, 71% of these patients were...
National Cancer Groups Release Joint Statement to Chart the Future of Cancer Health Disparities Research
Several national cancer organizations have released a joint position statement to guide the future of cancer health disparities research. The statement, which was published by Polite et al in Cancer Research, represents a unified strategy by the American Association for Cancer Research (AACR), the...
Response to CAR T-Cell Therapy After Ibrutinib in Chronic Lymphocytic Leukemia
As reported by Turtle et al in the Journal of Clinical Oncology, anti-CD19 chimeric antigen receptor–modified (CAR) T-cell therapy produced high response rates in patients with chronic lymphocytic leukemia previously treated with ibrutinib (Imbruvica). Study Details In the phase I/II study, ...
Classifying Gastric Cancers by Subtype May Provide Tailored Treatment Options
Gastric cancer is the third leading cause of cancer death in both men and women worldwide. In 2014, The Cancer Genome Atlas (TCGA) project discovered there are four molecular subtypes of gastric cancer: Epstein-Barr virus (EBV), microsatellite instability (MSI), genomically stable (GS), and...
Surgery vs Observation in Localized Prostate Cancer: Long-Term Follow-up of PIVOT Trial
After 19.5 years of follow-up in the PIVOT trial, radical prostatectomy was not associated with significantly improved all-cause or prostate cancer mortality vs observation among men with localized prostate cancer. The long-term follow-up data were reported in The New England Journal of Medicine by ...
NCI-COG Pediatric MATCH Trial to Test Targeted Drugs in Childhood Cancers
Today, investigators at the National Cancer Institute (NCI) and the Children’s Oncology Group (COG) announced the opening of enrollment for a unique precision medicine clinical trial. NCI-COG Pediatric Molecular Analysis for Therapy Choice (Pediatric MATCH) is a nationwide trial to explore...
FDA Expands Approval of Ipilimumab to Include Pediatric Patients 12 Years and Older With Unresectable or Metastatic Melanoma
Today, the U.S. Food and Drug Administration (FDA) expanded the indication for ipilimumab (Yervoy) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older. Ipilimumab was evaluated in 2 trials of pediatric...
Poor Social Functioning in Adolescent and Young Adult Cancer Survivors
A new study indicates many young adults who survived the disease struggle with “getting back to normal” as much as 2 years after their initial diagnosis. The longitudinal study, published by Husson et al in Cancer, is among the first seeking to understand the social functioning among...
COX-2 Inhibitors May Reverse IDO1-Mediated Immunosuppression in Some Cancers
In preclinical studies, tumors that consitutively expressed the protein indoleamine 2,3-dioxygenase (IDO1) responded to the cyclooxygenase-2 (COX-2) inhibitor celecoxib (Celebrex) and had improved infiltration of certain subsets of T cells, making them more likely to respond to...
Concurrent Chemotherapy, Proton Therapy May Improve Survival in Patients With Advanced Lung Cancer
For patients with advanced, inoperable stage III lung cancer, concurrent chemotherapy and proton-beam radiotherapy offers improved survival compared to historical data for standard of care, according to a new study from The University of Texas MD Anderson Cancer Center. The research, published by...
Neoadjuvant Ado-trastuzumab Emtansine vs Trastuzumab in Early HER2-Positive, HR-Positive Breast Cancer
A West German Study Group phase II trial, reported by Harbeck et al in the Journal of Clinical Oncology, has shown a higher pathologic complete response rate with neoadjuvant ado-trastuzumab emtansine (formerly known as T-DM1; Kadcyla) with or without endocrine therapy vs trastuzumab (Herceptin)...
Social Interaction May Affect Patients’ Response to Chemotherapy
How well patients with cancer fared after chemotherapy was affected by their social interaction with other patients during treatment, according to a new study by researchers at the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, and the University of...
Caregivers Have an Essential Role in Cancer Care. Help Them Be Prepared.
CANCER.NET offers caregiving tools and resources designed specifically for caregivers who are supporting someone with cancer. ASCO Answers Guide to Caregiving includes advice for talking with family and the health-care team, trackers for symptoms and medications, and more. Order this guide for...
Register Now for QOPI® QCDR for 2017 CMS MIPS Reporting: One Patient, One Measure, No Penalty
ASCO is pleased to announce that its Quality Oncology Practice Initiative (QOPI®) Qualified Clinical Data Registry (QCDR) is available now for the Centers for Medicare and Medicaid Services (CMS) Merit-Based Incentive Payment System (MIPS) reporting. By using the QOPI® QCDR for MIPS reporting,...
ASCO-AACI’s Best Practices in Cancer Clinical Trials Initiative: Streamlining Adverse Events Reporting and Research Community Forum Activities
Research sites and investigators face an ever-increasing number of challenges in the conduct and management of cancer clinical trials. Many of these challenges stem from the multitude of requirements for clinical trials that sponsors and regulatory and administrative agencies have set. In...
The Art of Networking: Advice for the Oncologist-in-Training
It was Friday night of the 2016 ASCO Annual Meeting in Chicago. I planned to meet a friend, another 2nd-year heme-onc fellow, at a “free drink thing,” as she called it. I sheepishly entered the hotel bar, made a nametag at the insistence of the greeter, and started edging my way through the crowd. ...
2017 ASTRO Gold Medalists Named
THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO) has announced the 2017 ASTRO Gold Medalists. Søren M. Bentzen, DSc, PhD; Louis B. Harrison, MD, FASTRO; and Michael L. Steinberg, MD, FASTRO, have been awarded the annual honor given to ASTRO members who have made outstanding lifetime...
Mike Heller, PhD, Joins OHSU Knight Cancer Institute
THE OREGON Health & Science University (OHSU) Knight Cancer Institute announced that bioengineering and technology expert Mike Heller, PhD, will join the Institute’s Cancer Early Detection Advanced Research Center (CEDAR) to lead its technology efforts. A leader with more than 53 issued...
Pembrolizumab and Cetuximab-Treated Head and Neck Cancer: Activity Confirmed But No Surprises
WITH THE RECENT efficacy findings, improvements in survival, and resultant U.S. Food and Drug Administration (FDA) approvals of programmed cell death protein 1 (PD-1) immune checkpoint inhibitors across multiple solid tumor indications, the publication of yet another positive trial adds to the...
Insurance Approval Rates for Enrollment in Oncology Clinical Trials Increased Under Affordable Care Act
The Patient Protection and Affordable Care Act (ACA) of 2010 was the first federal law to mandate that group health insurance plans and state-licensed insurance issuers provide coverage of standard-of-care costs for patients enrolled in approved clinical trials, effective on January 1, 2014. Under...
Understanding and Managing Radiation-Induced Bystander Effect
More than half of patients with cancer undergo radiotherapy. Due to a phenomenon known as radiation-induced bystander effect, in which irradiated cells leak chemical signals that can travel some distance to damage unexposed healthy cells, many suffer side effects such as hair loss, fatigue, and...
Analysis Reveals Genomic Alterations, Oncogenes Driving Medulloblastoma Subtypes
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75% of the brain tumors, including two new suspected cancer genes that were found exclusively in the least understood disease subgroups. The study from an international research...
Pembrolizumab Improves Overall Survival vs Chemotherapy in Second-Line Therapy for Advanced Urothelial Carcinoma
IN THE PHASE III KEYNOTE-045 trial reported in The New England Journal of Medicine, Joaquim Bellmunt, MD, PhD, of Dana-Farber Cancer Institute, and colleagues found that pembrolizumab (Keytruda) significantly improved overall survival vs investigator choice of chemotherapy as second-line treatment ...
NCCN Panelists Relay ‘What’s Hot’ in Their Fields
AT THE NATIONAL Comprehensive Cancer Network® (NCCN®) 22nd Annual Conference, experts from several fields met with journalists to highlight “what’s hot” in their specialties. The ASCO Post captured that conversation. Myeloproliferative Neoplasms Guidelines NCCN HAS LAUNCHED new NCCN Clinical...
Digital Tomosynthesis vs Mammography in Unmasking Breast Cancer
DIGITAL TOMOSYNTHESIS is rapidly replacing full-field digital mammography, because “it allows a more efficient diagnostic workflow and leads to a more confident interpretation,” according to Elizabeth A. Morris, MD, FACR, Chief of the Breast Imaging Service, Memorial Sloan Kettering Cancer Center, ...
Breast Cancer and Brain Metastases: Whole-Brain Radiotherapy May Not Be the Answer
FOR PATIENTS WITH BREAST CANCER who have metastases to the central nervous system (CNS), clinicians should think twice before administering whole-brain radiotherapy, according to Kimberly Blackwell, MD, Professor of Medicine and Assistant Professor of Radiation Oncology at Duke University Medical...
Are Wearable Physical Activity Monitors Coming of Age in Oncology?
COMMERCIALLY AVAILABLE wearable physical activity monitors have been making their way into clinical research in recent years; however, most studies on these devices have been related to non-cancer conditions including obesity, depression, and physical activity. Their application in the field of...
Expert Point of View: Anne Tsao, MD, and John Heymach, MD, PhD
STUDY DISCUSSANT Anne Tsao, MD, Director of the Mesothelioma Program at The University of Texas MD Anderson Cancer Center in Houston, indicated the response rates seen in the MAPS-2 trial are comparable to those demonstrated in smaller studies of pembrolizumab (Keytruda). She considered the...
Checkpoint Inhibitors May Prove to Be Effective in Mesothelioma
CHECKPOINT INHIBITION was effective against malignant pleural mesothelioma in the MAPS-2 study of the French Cooperative Thoracic Intergroup. At the 2017 ASCO Annual Meeting, researchers reported a disease control rate of up to 50% when patients were treated with immunotherapy after relapse in a...
Expert Point of View: Ritu Salani, MD, MBA
STUDY DISCUSSANT Ritu Salani, MD, MBA, of The Ohio State University Wexner Medical Center, Columbus, agreed with the LION trial investigators. “Omitting systemic lymph node dissection in patients who have both radiographic and clinically negative lymph nodes is acceptable,” she said. “I always...
Expert Point of View: Siwen Hu-Lieskovan, MD
“COMBINATION STRATEGIES are being developed, but the big question is what and how to combine,” said formal discussant Siwen Hu-Lieskovan, MD, of the University of California Los Angeles. “Anti–programmed cell death protein 1 (PD-1) therapy works at the last step of T-cell activation and relies on...
Combination Strategies for Jump-Starting the Immune Response
CHECKPOINT INHIBITORS have dramatically changed the landscape of the treatment of melanoma, lung, bladder, and other cancers. Researchers are focusing on exploring ways to extend the use of checkpoint inhibitors to other disease states and to combine them with novel agents and improve outcomes. At ...
Expert Point of View: Steven J. Cohen, MD, and Josep Tabarnero, MD, PhD
STEVEN J. COHEN, MD, Director of the Rosenfeld Cancer Center at Jefferson Health/Abington Hospital, Abington, Pennsylvania, and Vice Chair of Medical Oncology at Sidney Kimmel Cancer Center at Jefferson, and Josep Tabernero, MD, PhD, Head of Medical Oncology and the Gastrointestinal Tumors and...
